Cited by 80Neuroendocrine Tumor Research AdvancesPancreatic function and diabetesAbdominal vascular conditions and treatments

Selective Arterial Calcium Stimulation With Hepatic Venous Sampling Differentiates Insulinoma From Nesidioblastosis

Open access
Thompson, Scott M., Vella, Adrian, Thompson, Geoffrey B., Rumilla, Kandelaria M., Service, F. John, Grant, Clive S., Andrews, James C.·2015·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: In adult patients with endogenous hyperinsulinemic hypoglycemia and negative or inconclusive noninvasive imaging, insulinoma and non-insulinoma pancreatogenous hypoglycemic syndrome (NIPHS) resulting from diffuse nesidioblastosis must be considered in the differential diagnosis. It is not known whether the biochemical results of selective arterial calcium stimulation (SACST) with hepatic venous sampling can differentiate insulinoma from diffuse nesidioblastosis. OBJECTIVE: To determine the specificity of SACST with hepatic venous sampling in differentiating insulinoma from diffuse nesidioblastosis. DESIGN: Retrospective review (January 1996 to March 2014). SETTING: Tertiary referral center. PATIENTS OR OTHER PARTICIPANTS: A total of 116 patients with biochemical evidence of endogenous hyperinsulinemic hypoglycemia and negative or inconclusive noninvasive imaging who were subsequently shown at surgery to have insulinoma (n = 42) or nesidioblastosis (n = 74) after undergoing SACST with hepatic venous sampling. INTERVENTION(S): SACST with hepatic venous sampling before pancreatic exploration. MAIN OUTCOME MEASURE(S): Receiver operating characteristic curves were generated from the biochemical results of SACST to determine the specificity of the maximum hepatic venous insulin concentration (mHVI) and the relative-fold increase in hepatic venous insulin concentration (rHVI) over baseline after calcium injection from the dominant artery in differentiating insulinoma from nesidioblastosis. RESULTS: The mHVI (21.5-fold; P < .001) and rHVI (3.9-fold; P < .001) were significantly higher in the insulinoma group compared to the nesidioblastosis group. The areas under the receiver operating characteristic curve for mHVI and rHVI were excellent (0.94; P < .0001) and good (0.83; P < .0001), respectively, for differentiating insulinoma from nesidioblastosis. mHVI cutoffs of > 91.5 and > 263.5 μIU/mL were 95 and 100% specific for insulinoma, respectively. A 19-fold increase in rHVI over baseline was 99% specific for insulinoma. CONCLUSIONS: These data suggest that the mHVI and rHVI at SACST may be useful in differentiating insulinoma from nesidioblastosis with high specificity in patients with hyperinsulinemic hypoglycemia and negative or inconclusive noninvasive imaging.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2015-2404

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SACS was the gold standard in the past to detect an insulin gradient in the vessels supplying the pancreas, and this invasive method might be almost completely replaced by PET imaging in the future, e.g., with 68Ga DOTA-Exendin-4 PET/CT.

    “While SACS was the gold standard in the past to detect an insulin gradient in the vessels supplying the pancreas, this invasive method might be almost completely replaced by PET imaging in the future, e.g., with 68 Ga DOTA-Exendin-4 PET/CT [38-41].”

    From An Uncommon Cause of Recurrent Presyncope, Dizziness, and Tachycardia: A Case Report of Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) (2023) · cites this paper as [38]

    The Discussion describes SACST as an invasive technique that measures an insulin rise after stimulation of pancreatic arterial distributions and reports high sensitivity for localizing occult insulinoma. It does not call SACST a past gold standard or predict its near-complete replacement by PET. Instead, the Discussion says emerging imaging techniques show promising early results but cannot yet distinguish occult insulinoma from diffuse nesidioblastosis. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [5]5. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19(5):783–798. [DOI] [PubMed] [Google Scholar]

Cited by

Sorted by citations

Authors
Thompson, S. M., Vella, A., Thompson, G. B., Rumilla, K. M., Service, F. J., Grant, C. S., & Andrews, J. C.
Affiliations
Mayo Clinic (US)
Corresponding author
Thompson, Scott M.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2015-11
Volume
100
Issue
11
Pages
4189-4197
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2109360431
Cited by
80
References
41
Citations by year
2026: 5 · 2025: 6 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 6 · 2020: 6 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 8 · 2013: 1
FWCI
6.28
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (TL1TR000137)
  • Guangdong Academy of Sciences
  • Norwegian Institute of Public Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK078646)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Surgery › Abdominal vascular conditions and treatments
Keywords
insulinoma, nesidioblastosis, hepatic venous sampling, hyperinsulinemic hypoglycemia, differential diagnosis, diagnostic specificity, hepatic insulin secretion, receiver operating characteristic
MeSH terms
Adult, Aged, Calcium, Diagnosis, Differential, Female, Hepatic Veins, Humans, Hyperinsulinism, Hypoglycemia, Insulinoma, Male, Middle Aged, Pancreatic Neoplasms, Retrospective Studies, ROC Curve, Body Mass Index, Nesidioblastosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review